The effect of salvage therapy on survival in a longitudinal study with treatment by indication.
We consider using observational data to estimate the effect of a treatment on disease recurrence, when the decision to initiate treatment is based on longitudinal factors associated with the risk of recurrence. The effect of salvage androgen deprivation therapy (SADT) on the risk of recurrence of prostate cancer is inadequately described by the existing literature. Furthermore, standard Cox regression yields biased estimates of the effect of SADT, since it is necessary to adjust for prostate-specific antigen (PSA), which is a time-dependent confounder and an intermediate variable. In this paper, we describe and compare two methods which appropriately adjust for PSA in estimating the effect of SADT. The first method is a two-stage method which jointly estimates the effect of SADT and the hazard of recurrence in the absence of treatment by SADT. In the first stage, PSA is predicted in the absence of SADT, and in the second stage, a time-dependent Cox model is used to estimate the benefit of SADT, adjusting for PSA. The second method, called sequential stratification, reorganizes the data to resemble a sequence of experiments in which treatment is conditionally randomized given the time-dependent covariates. Strata are formed, each consisting of a patient undergoing SADT and a set of appropriately matched controls, and analysis proceeds via stratified Cox regression. Both methods are applied to data from patients initially treated with radiation therapy for prostate cancer and give similar SADT effect estimates.
Kennedy
Edward H
EH
Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
Taylor
Jeremy M G
JM
Schaubel
Douglas E
DE
Williams
Scott
S
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D015986:Confounding Factors, Epidemiologic; D003627:Data Interpretation, Statistical; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D018570:Risk Assessment; D016879:Salvage Therapy; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen
Eur Urol. 1998;33(1):39-53
9471040
J Am Stat Assoc. 2001;96(455):
24204084
Am J Epidemiol. 2007 Nov 1;166(9):985-93
17875580
Biometrics. 1997 Mar;53(1):330-9
9147598
J Clin Endocrinol Metab. 1991 Nov;73(5):1016-25
1719016
Int J Biostat. 2007;3(1):Article 3
19122793
Cochrane Database Syst Rev. 2002;(1):CD003506
11869665
Stat Med. 1989 Jun;8(6):679-701
2749074
Biometrics. 2005 Sep;61(3):721-8
16135023
Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):237-42
16611197
Cancer. 1993 Jul 15;72(2):538-48
7686443
JAMA. 2005 Jul 13;294(2):238-44
16014598
Stat Med. 1998 Sep 30;17(18):2061-77
9789914
Cancer. 2008 Jan 15;112(2):307-14
18050294
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):782-91
19014779
JAMA. 1999 May 5;281(17):1598-604
10235152
Biometrics. 2006 Sep;62(3):910-7
16984335
J Androl. 1991 Nov-Dec;12(6):376-80
1722793
J Clin Oncol. 2006 Sep 20;24(27):4448-56
16983113